Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas

被引:21
作者
Fabbri, Alberto [1 ]
Cencini, Emanuele [1 ]
Alterini, Renato [2 ]
Rubegni, Pietro [3 ]
Rigacci, Luigi [2 ]
Delfino, Chiara [4 ]
Puccini, Benedetta [2 ]
Fimiani, Michele [3 ]
Bosi, Alberto [2 ]
Bocchia, Monica [1 ]
Pimpinelli, Nicola [4 ]
机构
[1] Univ Hosp Siena, Div Haematol, Siena, Italy
[2] Univ Hosp Florence, Div Haematol, Florence, Italy
[3] Univ Hosp Siena, Div Dermatol, Siena, Italy
[4] Univ Florence, Med Sch & Hlth Dist, Dept Surg & Translat Med, Div Dermatol, Florence, Italy
关键词
primary cutaneous B-cell lymphomas; treatment; rituximab; liposomal pegylated doxorubicin; WHO-EORTC CLASSIFICATION; TREATMENT-OF-CANCER; EUROPEAN-ORGANIZATION; FOLLOW-UP; MYCOSIS-FUNGOIDES; FOLLICULAR LYMPHOMA; ANTIBODY RITUXIMAB; PROGNOSTIC-FACTORS; HODGKINS-LYMPHOMA; CHEMOTHERAPY;
D O I
10.1111/ejh.12315
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In primary cutaneous B-cell lymphomas (PCBCL), radiotherapy - or surgery in a minority of cases - is the first-line treatment in follicle center lymphoma (PCFCL) and marginal zone B-cell lymphoma (PCMZL). Conversely, patients with multifocal skin involvement or relapsed/refractory disease deserve a systemic chemotherapy. In diffuse large B-cell lymphoma, leg type (PCLBCL-LT), due its poorer outcome, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like regimens are the most commonly used frontline, although hard to propose in elderly patients. In this regard, the association of rituximab (R) and pegylated liposomal doxorubicin (PLD) can be considered a promising, alternative approach. Aims: Based on the favorable results reported with R and PLD in several recent trials, we decided to test efficacy and safety of this combination. Methods: Twelve patients with PCBCL were treated with R plus PLD, and 7 had relapsed disease. Treatment plan consisted of 2 monthly cycles of R 375 mg/m(2) and PLD 20 mg/m(2) day 1; 15, followed (in responders) by two cycles given only at day 1. All patients received prophylactic pyridoxine to prevent palmar-plantar erythrodysesthesia (PPE). Results: Ten of 12 patients had a response (eight complete; two partial), remarkably 2/3 with PCLBCL-LT. Two patients did not respond (one progressive disease, PD, and one stable disease). Three patients died after a median follow-up of 56 months, two patients due to PD, and 1 due to a second neoplasm. Two out of 10 responders relapsed after 31 and 32 months, respectively. Hematological toxicity was negligible (one case of grade 2 neutropenia), as well as extra-hematological toxicity (two cases of grade 2 PPE). Conclusions: These preliminary data suggest that R-PLD is effective and well tolerated in all subsets of PCBCL and may be offered frontline in indolent cases unsuitable for radiotherapy or surgery as well as in more aggressive cases with contraindications to CHOP-like regimens.
引用
收藏
页码:129 / 136
页数:8
相关论文
共 53 条
  • [1] Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma
    Avilés, A
    Neri, N
    Castañeda, C
    Talavera, A
    Huerta-Guzmán, J
    González, M
    [J]. MEDICAL ONCOLOGY, 2002, 19 (01) : 55 - 58
  • [2] Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
    Bartlett, N. L.
    Niedzwiecki, D.
    Johnson, J. L.
    Friedberg, J. W.
    Johnson, K. B.
    van Besien, K.
    Zelenetz, A. D.
    Cheson, B. D.
    Canellos, G. P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (06) : 1071 - 1079
  • [3] Bogle MA, 2005, J AM ACAD DERMATOL, V53, P479
  • [4] Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas
    Brandenburg, A.
    Humme, D.
    Terhorst, D.
    Gellrich, S.
    Sterry, W.
    Beyer, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (05) : 1126 - 1132
  • [5] From conventional to stealth liposomes: a new frontier in cancer chemotherapy
    Cattel, L
    Ceruti, M
    Dosio, F
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 : 94 - 97
  • [6] Multiple injections of pegylated liposomal doxorubicin: Pharmacokinetics and therapeutic activity
    Charrois, GJR
    Allen, TM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (03) : 1058 - 1067
  • [7] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [8] Chow KU, 2002, HAEMATOLOGICA, V87, P33
  • [9] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [10] Intra-lesional low-dose interferon α2a therapy for primary cutaneous marginal zone B-cell lymphoma
    Cozzio, Antonio
    Kempf, Werner
    Schmid-Meyer, Regula
    Gilliet, Michel
    Michaelis, Sonja
    Schaerer, Leo
    Burg, Guenter
    Dummer, Reinhard
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (05) : 865 - 869